Information Provided By:
Fly News Breaks for October 15, 2015
SYK, NUVA, GMED
Oct 15, 2015 | 07:56 EDT
Brean Capital said the recent selloff in healthcare has led to a buying opportunity for the standalone spine companies. The firm believes the group is poised to report solid quarterly results due to improved volumes and reimbursement conditions. The firm reiterated its Buy rating and $33 price target on Globus Medical (GMED), reiterated its Buy rating and $56 price target on Nuvasive (NUVA), and maintained its Hold rating on Stryker (SYK) shares.
News For GMED;NUVA;SYK From the Last 2 Days
There are no results for your query GMED;NUVA;SYK